TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19249029

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without PGS
Number of subjects: 0
Study: 17084512

Group type: EXPERIMENTAL
Intervention: Arm A: vinblastine (0.2 mg/kg on day 1), etoposide (100 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and bleomycin (30 mg on days 1, 8, and 15)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Arm B: etoposide (350 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and cyclophosphamide (1600 mg/m2/d on days 2-5)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 115

Group type: COMPARATOR
Intervention: Arm B
Number of subjects: 115
Study: 16218350

Group type: EXPERIMENTAL
Intervention: Detralex (treated for 14 days before and after surgery)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Not treated with Detralex (control group)
Number of subjects: 181
Study: 12097444

Group type: EXPERIMENTAL
Intervention: Dentist informed of MDAS score
Number of subjects: 119

Group type: COMPARATOR
Intervention: Dentist not informed of MDAS score
Number of subjects: 119
Study: 10073421

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lithium treatment (61 to 240 mo)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lithium treatment (0.7 to 6 mo)
Number of subjects: 132
Study: 7675967

Group type: EXPERIMENTAL
Intervention: Pindolol pretreatment (2 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: (+)-fenfluramine (30 mg po)
Number of subjects: 9
Study: 2105409

Group type: EXPERIMENTAL
Intervention: Formaldehyde vapor exposure at levels of 0.85 mg/m3, 0.12 mg/m3, and 0.008 mg/m3 for 90 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formaldehyde vapor exposure
Number of subjects: 15
Study: 6255005

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (1.2-2.5 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31836196

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg, increased to 300 mg as tolerated)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 30231896

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous (SC) 300 mg crenezumab every 2 weeks for 68 weeks
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-dose intravenous (IV) 15 mg/kg crenezumab every 4 weeks for 68 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 27431341

Group type: EXPERIMENTAL
Intervention: Psychoeducation with problem-solving (PEPS) therapy plus usual treatment
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual treatment alone
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Psychoeducation with problem-solving (PEPS) therapy
Number of subjects: 306
Study: 25514875

Group type: EXPERIMENTAL
Intervention: Phototherapy (Group A: 2.62 Joules)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Phototherapy (Group B: 5.24 Joules)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Phototherapy (Group C: 7.86 Joules)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo therapy (Group D: 0 Joules)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 72
Study: 22661616

Group type: EXPERIMENTAL
Intervention: Greater family organization
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Greater self-efficacy for diabetes management
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: More family organization
Number of subjects: 257
Study: 19606453

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink plus alcohol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink alone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-alcoholic, non-caffeinated control beverage
Number of subjects: 27
Study: 17453860

Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.1 mg NETA
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.25 mg NETA
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study: 15168036

Group type: EXPERIMENTAL
Intervention: Olive oils with increasing phenolic concentration (0 to 150 mg/Kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Virgin olive oil with high phenolic content
Number of subjects: 30
Study: 12114917

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (3 doses, 800 microg each)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 12
Study: 10049275

Group type: EXPERIMENTAL
Intervention: Abacavir 4 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Abacavir 8 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Abacavir (both doses)
Number of subjects: 22
Study: 7586985

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sulphasalazine (SSZ)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 67
Study: 2159264

Group type: EXPERIMENTAL
Intervention: Tegafur‐Uracil (UFT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: FT‐207
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: UFT
Number of subjects: 76
Study: 526385

Group type: EXPERIMENTAL
Intervention: Ketamine i.v. infusion
Number of subjects: 31
Study: 31661171

Group type: EXPERIMENTAL
Intervention: Figure-of-eight suture (F8)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Manual pressure (MP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 29104459

Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (casein, 30 g/d)
Number of subjects: 43
Study: 24519448

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus laser therapy (ice chips for 1 h 35 min followed by low-level laser therapy, InGaAIP, 660 nm, 40 mW, 6 J/cm(2), n = 54)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Laser therapy alone (n = 17)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no specific treatment for OM, n = 33)
Number of subjects: 71
Study: 23440253

Group type: EXPERIMENTAL
Intervention: Weekly volunteering with elementary school‐aged children for 2 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 106
Study: 22356030

Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TTH group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 19524329

Group type: EXPERIMENTAL
Intervention: Periodic physical activity, recreational activities, nutritional and food manipulation training visits, with a medical student assigned for periodical contact.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Normal activities during observational period.
Number of subjects: 700
Study: 16574041

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1295
Study: 10525745

Group type: EXPERIMENTAL
Intervention: Triple the maintenance dose every 72 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Double the maintenance dose every 48 h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Maintenance dose every 24 h
Number of subjects: 16
Study: 8546911

Group type: EXPERIMENTAL
Intervention: ICR62 2.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ICR62 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ICR62 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ICR62 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ICR62 100 mg
Number of subjects: 20
Study: 1884746

Group type: EXPERIMENTAL
Intervention: HR (2 tablets of 500 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6346476

Group type: EXPERIMENTAL
Intervention: Cisobitan
Number of subjects: 140

Group type: COMPARATOR
Intervention: Estradurin/Etivex (estrogen preparation)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cisobitan (poorly differentiated cancer)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Estracyt (poorly differentiated cancer)
Number of subjects: 140
Study: 31525174

Group type: EXPERIMENTAL
Intervention: Triaxial accelerometry (ActiGraph GT3X+) measuring physical activity intensity across three axes
Number of subjects: 841

Group type: COMPARATOR
Intervention: Overall PA (counts per minute) from the vertical axis only
Number of subjects: 841
Study: 29370756

Group type: EXPERIMENTAL
Intervention: Center-based (CB) exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based (HB) exercise
Number of subjects: 0
Study: 27327283

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ranibizumab 1.0 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg and 1.0 mg
Number of subjects: 46
Study: 24445223

Group type: EXPERIMENTAL
Intervention: Physician telepresence (PTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional nurse triage (TNT)
Number of subjects: 0
Study: 22045039

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (150 and 300 mg/day)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day and Escitalopram
Number of subjects: 874
Study: 21146654

Group type: EXPERIMENTAL
Intervention: Standard activated clotting time (ACT)-guided doses of intravenous UFH
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Non-ACT-guided weight-adjusted low dose of intravenous UFH
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Both regimens (Standard and Low-dose)
Number of subjects: 4000
Study: 17986897

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined Training (CT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study: 16282047

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatments for OA
Number of subjects: 0
Study: 11980684

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 1008
Study: 9499327

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Thalidomide 300 mg/d
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d and 300 mg/d
Number of subjects: 96
Study: 8907436

Group type: EXPERIMENTAL
Intervention: Breast-fed infants (one month and three months of age)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula-fed infants (one month and three months of age)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control serum from healthy adults (22 to 30 years of age)
Number of subjects: 0
Study: 31563366

Group type: EXPERIMENTAL
Intervention: Dry cupping on calf muscle myofascial trigger points (MTrPs)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Stretching exercises and ankle dorsiflexion exercises
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 71
Study: 29190605

Group type: EXPERIMENTAL
Intervention: High dose of colistin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional dose of colistin
Number of subjects: 40
Study: 25622198

Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation (CSC) intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Delayed smoking cessation (DSC) intervention
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Daily assessments during CSC
Number of subjects: 151
Study: 23398585

Group type: EXPERIMENTAL
Intervention: Affective suppression condition
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Positive mindset condition
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 127
Study: 21496653

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 4% articaine with 1:100,000 epinephrine
Number of subjects: 86
Study: 21246795

Group type: EXPERIMENTAL
Intervention: Cranberry extract capsules (equiv. 17,000 mg of fresh fruit) taken twice a day, 4 days before and 5 days after surgery
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (no cranberry extract)
Number of subjects: 286
Study: 17473001

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15058118

Group type: EXPERIMENTAL
Intervention: Prepared morphine solution 10 mg (Group Ten)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prepared morphine solution 5 mg (Group Five)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No syringe (Group Zero)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prepared morphine solution (Group Ten and Group Five)
Number of subjects: 105
Study: 11464349

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (0.166%, 2 to 8 mL/h) and diamorphine (0.2 to 0.8 mg/h) for 24 hours before and during operation (14 patients)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intraoperative perineural catheter infusing bupivacaine (0.25%, 10 mL/h) (16 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Perineural group
Number of subjects: 30
Study: 9483593

Group type: EXPERIMENTAL
Intervention: Interactive teaching book
Number of subjects: 143

Group type: COMPARATOR
Intervention: Routine preoperative teaching (Control)
Number of subjects: 143
Study: 7993161

Group type: EXPERIMENTAL
Intervention: Intervention group (verbal instructions and handout about medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual discharge instructions)
Number of subjects: 0
Study: 2910050

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin, 0.2 mg/kg per dose, three doses on the fourth day of life
Number of subjects: 38

Group type: COMPARATOR
Intervention: No indomethacin (control group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Infants without evidence of a PDA (third group)
Number of subjects: 38
Study: 790351

Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride 32 mg daily for 16 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 28
Study: 28616796

Group type: EXPERIMENTAL
Intervention: Bilateral topical anesthetic eye drops (Group 2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ipsilateral topical anesthetic eye drops (Group 1)
Number of subjects: 180
Study: 28610898

Group type: EXPERIMENTAL
Intervention: Immediate insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) within 5 days of delivery
Number of subjects: 205

Group type: COMPARATOR
Intervention: Delayed insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) at 6 weeks postpartum
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Immediate insertion of levonorgestrel contraceptive implants
Number of subjects: 205

Group type: COMPARATOR
Intervention: Delayed insertion of levonorgestrel contraceptive implants
Number of subjects: 205
Study: 25434574

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (15% energy restricted diet for 4 weeks)
Number of subjects: 50
Study: 21679246

Group type: EXPERIMENTAL
Intervention: Single dose of 250, 500, 1000, 1250 or 1500 mg of mildronate capsules
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiple dose of 500 mg of mildronate capsules three times a day for 13 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tolerability assessment throughout the study
Number of subjects: 40
Study: 21695630

Group type: EXPERIMENTAL
Intervention: Dianxianning
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 19728630

Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total excision (control)
Number of subjects: 0
Study: 17172616

Group type: EXPERIMENTAL
Intervention: Pramipexole treatment
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cumulative levodopa dose
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cumulative levodopa equivalent dose (levodopa plus pramipexole)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Age at onset of 65 years or older
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Hoehn and Yahr stage of 2 or higher
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Occurrence of motor fluctuations
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Cumulative levodopa equivalent dose
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Motor fluctuations and dyskinesias
Number of subjects: 301
Study: 14743580

Group type: EXPERIMENTAL
Intervention: Cholesterol-enriched lipid emulsion (4 g/l free cholesterol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional lipid emulsion (20% triglycerides)
Number of subjects: 10
Study: 11070454

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg) dry-powder inhalation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8878166

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (C, E, beta carotene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational epidemiology
Number of subjects: 0
Study: 1349492

Group type: EXPERIMENTAL
Intervention: abanoquil 0.25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: abanoquil 0.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: abanoquil 1 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 3899971

Group type: EXPERIMENTAL
Intervention: Benzydamine vaginal douche
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 30956216

Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis (150 mg IV bolus, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis
Number of subjects: 46
Study: 30015649

Group type: EXPERIMENTAL
Intervention: Couple-based interventions addressing traditional cardiovascular risk factors; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment-based interventions, such as the Healing Hearts Together program; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Couple-based interventions; details on dosage and duration not available.
Number of subjects: 0
Study: 26437831

Group type: EXPERIMENTAL
Intervention: Digestion-resistant maltodextrin (RMD)
Number of subjects: 66
Study: 25135729

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture stimulation (EAS) at PC4 and PC6
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (general anesthesia only)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham (EA needles at PC4 and PC6 but no stimulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study: 22574587

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (AD) 10 mg, once daily, combined with Baihua Xianglian Detoxification Recipe (BXDR) twice daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Baihua Xianglian Detoxification Recipe (BXDR) combined with Adefovir dipivoxil (AD)
Number of subjects: 240
Study: 21240151

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 400 mg/day
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg/day
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 800 mg/day
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Quetiapine IR 800 mg/day
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study: 17912637

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for up to 5 years
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily for up to 5 years
Number of subjects: 4000
Study: 15590845

Group type: EXPERIMENTAL
Intervention: Kapandji method (modified by Fritz et al.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Kirschner wire fixation (Willenegger technique)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Kapandji method
Number of subjects: 100
Study: 12600115

Group type: EXPERIMENTAL
Intervention: Intravenous reduced glutathione (GSH) at a dose of 1200 mg twice a week for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 3000U twice a week for 12 weeks
Number of subjects: 42
Study: 9700247

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fibers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing only
Number of subjects: 30
Study: 7981015

Group type: EXPERIMENTAL
Intervention: Vinpocetine (10 mg three times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxazepam (10 mg three times daily)
Number of subjects: 16
Study: 2597598

Group type: EXPERIMENTAL
Intervention: Inderex (bendrofluazide 5 mg and Inderal LA 160 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Inderal LA (160 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bendrofluazide (5 mg)
Number of subjects: 21
Study: 4881072

Group type: EXPERIMENTAL
Intervention: Leningrad-16
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Schwarz
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100